Pediatric Combination Vaccines: Global Drug Forecast and Market Analysis to 2028

Well-organized immunization schedules for infants, children, and adolescents are the cornerstone of public health campaigns in most developed and developing countries. In particular, vaccines are the most effective method of protecting the general population and select groups of people against infectious diseases. In the US alone, childhood vaccines are estimated to prevent 14 million infections, avoid 33,000 premature deaths annually, and save $43bn in direct and indirect costs for each fully vaccinated US birth cohort. Across the nine major pharmaceutical markets (9MM; US, France, Germany, Italy, Spain, UK, Japan, Canada, India), routine childhood vaccination schedules include a series of vaccines that afford protection against approximately infectious diseases. The gradual introduction of combination vaccines which can protect against a greater number of these diseases has dramatically reduced the number of injections required, without sacrificing protective efficacy.

Key Questions Answered

How will the pediatric combination vaccine therapeutic market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, India, Canada) change from 2018–2028?

What routine pediatric vaccines are in clinical development?

How do the clinical and commercial attributes of pediatric vaccines in development compare with one another, and against existing vaccines?

What are the remaining unmet needs in routine pediatric vaccinations?

What drivers and barriers will affect routine pediatric vaccine sales in the 9MM over the forecast period?

Scope

Overview of vaccines used in routine immunization of infants and children for DTaP, Tdap, IPV, HBV, Hib, HAV, MMR, varicella, rotavirus, and Japanese encephalitis.

Topline pediatric vaccine market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include currently available vaccines, unmet needs and opportunities, and the drivers and barriers affecting pediatric vaccine sales in the 9MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.

Analysis of the current and future market competition in the global pediatric vaccines market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Over the 10-year forecast period, GlobalData expects the 9MM pediatric combination vaccines market to shrink at a negative CAGR of 0.9%, from $7.7bn in 2018 to $7.0bn in 2028. Individual markets will undergo significantly different changes, with the US market expected to grow at a CAGR of 1.1%, whereas the India market is expected to contract at a negative CAGR of 6.5%.

GlobalData expects the main driver of growth during the forecast period to be the US launch of Merck and Sanofi’s Vaxelis, in 2020. As the first available hexavalent DTaP vaccine in the US, it will rapidly garner market share; by 2028 it is expected be used in almost a third of all DTaP vaccinations.

Throughout the forecast period, vaccine hesitancy is anticipated to remain a challenge to public health bodies, particularly in North America and Europe. GlobalData expects that government policy changes will help to reduce the impact on vaccination rates because of the public awareness of the issues posed by misinformation online.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global pediatric vaccines market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the pediatric combination vaccines market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Merck & Co

Sanofi

GlaxoSmithKline

Serum Institute of India

Shantha Biotech

Takeda

Mitsubishi Tanabe

Cadila Healthcare

KM Biologics

Merck & Co

Sanofi

GlaxoSmithKline

Serum Institute of India

Shantha Biotech

Takeda

Mitsubishi Tanabe

Cadila Healthcare

KM Biologics

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Pediatric Combination Vaccines: Executive Summary

2.1 Domestically Produced Vaccines in India will ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Pediatric Combination Vaccines: Executive Summary

2.1 Domestically Produced Vaccines in India will drive 9MM Market Contraction

2.2 Ability to Bundle Pediatric Vaccines is Key to Commercial Success

2.3 Vaccine Hesitancy Is a Major Threat to Public Health

2.4 Domestic Suppliers to Dominate Future Market in India and Japan

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Overview of Vaccine Preventable Diseases

4.1 Summary

4.2 Diseases

4.2.1 Gram-Positive Bacterial Infections

4.2.2 Gram-Negative Bacterial Infections

4.2.3 RNA Viral Infections

4.2.4 DNA Viral Infections

4.3 Pathogens

5 Epidemiology

5.1 Disease Background

5.2 Risk Averted by Childhood Vaccinations

5.3 Global and Historical Trends

5.3.1 North America

5.3.2 Europe

5.3.3 Asia

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Pediatric Vaccination Rates in the Total Population

5.5 Epidemiological Forecast for Pediatric Vaccines (2018–2028)

5.5.1 US Vaccinated Pediatric Population

5.5.2 France Vaccinated Pediatric Population

5.5.3 Germany Vaccinated Pediatric Population

5.5.4 Italy Vaccinated Pediatric Population

5.5.5 Spain Vaccinated Pediatric Population

5.5.6 UK Vaccinated Pediatric Population

5.5.7 Japan Vaccinated Pediatric Population

5.5.8 Canada Vaccinated Pediatric Population

5.5.9 India Vaccinated Pediatric Population

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Immunization Recommendations and Schedules

6.1 Overview

6.2 US

6.3 5EU

6.3.1 France

6.3.2 Germany

6.3.3 Italy

6.3.4 Spain

6.3.5 UK

6.4 Japan

6.5 India

6.6 Canada

7 Competitive Assessment

7.1 Overview

7.2 DTaP

7.3 MMR and Varicella

7.4 Rotavirus

7.5 Japanese Encephalitis

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Combatting Vaccine Hesitancy

8.3 Consistent Immunization Across Demographics

8.3.1 Age Groups

8.3.2 Rural Versus Urban

8.3.3 Regional Differences

8.4 Vaccines with Improved Safety, Duration of Protection, and Coverage

8.5 Expansion of Immunization Programs

9 Pipeline Assessment

9.1 Overview

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 GlaxoSmithKline

10.3.2 Merck & Co.

10.3.3 Sanofi Pasteur

10.3.4 Serum Institute of India

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 India

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 Canada

11.6.1 Forecast

11.6.2 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Number of Vaccinations Administered

12.3.3 Drugs Included in Each Therapeutic Class

12.3.4 Launch Dates

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions

12.3.7 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Pediatric Combination Vaccines: Key Metrics in the 9MM

Table 2: Diseases Preventable Through Routine Pediatric Immunizations

Table 3: Summary of the Key Characteristics ...

Table 1: Pediatric Combination Vaccines: Key Metrics in the 9MM

Table 2: Diseases Preventable Through Routine Pediatric Immunizations

Table 3: Summary of the Key Characteristics of the Pathogens Responsible for Each Vaccine-Preventable Disease

Table 4: Global Impact of Major Childhood Vaccines in Reducing Morbidity and Mortality

Table 5: Pediatric Vaccination Rate Trends in North America (%)

Table 6: Pediatric Vaccination Rate Trends in Europe (%)

Table 7: Pediatric Vaccination Rate Trends in Asia (%)

Table 8: Public Health Organizations Governing National Immunization Schedules Across the 9MM

Table 9: Leading Routine DTaP Combination Pediatric Vaccines, 2019

Table 10: Leading Routine MMR Combination Pediatric Vaccines, 2019

Table 11: Leading Routine Rotavirus Combination Pediatric Vaccines, 2018

Table 12: GlaxoSmithKline’s Routine Pediatric Vaccines Portfolio Assessment, 2018

Table 13: Merck’s Routine Pediatric Vaccines Portfolio Assessment, 2018

Table 14: Sanofi’s Routine Pediatric Vaccines Portfolio Assessment, 2018

Table 15: Serum’s Routine Pediatric Vaccines Portfolio Assessment, 2018

Table 16: Pediatric Combination Vaccine Market – Global Drivers and Barriers, 2018–2028

Table 17: Key Events Impacting Sales of Pediatric Combination Vaccines in the US, 2018–2028

Table 18: Pediatric Combination Vaccines Market – Drivers and Barriers in the US, 2018–2028

Table 19: Key Events Impacting Sales of Pediatric Combination Vaccines in the 5EU, 2018–2028

Table 20: Pediatric Combination Vaccines Market – Drivers and Barriers in the 5EU, 2018–2028

Table 21: Key Events Impacting Sales of Pediatric Combination Vaccines in Japan, 2018–2028

Table 22: Pediatric Combination Vaccine Market – Global Drivers and Barriers in Japan, 2018–2028

Table 23: Key Events Impacting Sales of Pediatric Combination Vaccines in India, 2018–2028

Table 24: Pediatric Combination Vaccines Market – Drivers and Barriers in the India, 2018–2028

Table 25: Pediatric Combination Vaccines Market – Global Drivers and Barriers in Canada, 2018–2028

Table 26: Key Historical and Projected Launch Dates for Pediatric Combination Vaccines

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Pediatric Combination Vaccines in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in Pediatric ...

Figure 1: Global Sales Forecast by Country for Pediatric Combination Vaccines in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in Pediatric Combination Vaccines During the Forecast Period

Figure 3: Competitive Assessment of the Recently Approved and Late-Stage Pipeline Agents that GlobalData Expects to be launched During the Forecast Period

Figure 4: 9MM, Sources Used and Not Used for the Vaccinated Pediatric Population

Figure 5: US, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 6: France, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 7: Germany, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 8: Italy, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 9: Spain, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 10: UK, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 11: Japan, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 12: Canada, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 13: India, Vaccinated Pediatric Population, Boys and Girls, 2018 and 2028

Figure 14: Schedule for Pediatric Vaccines in the US, 2018

Figure 15: Measles Vaccination Rates in the 5EU, 2006–2016.

Figure 16: Schedule for Pediatric Vaccines in France, 2018

Figure 17: Schedule for Pediatric Vaccines in Germany, 2018

Figure 18: Schedule for Pediatric Vaccines in Italy, 2018

Figure 19: Schedule for Pediatric Vaccines in Spain, 2018

Figure 20: Schedule for Pediatric Vaccines in the UK, 2018

Figure 21: Schedule for Pediatric Vaccines in Japan, 2017

Figure 22: Schedule for Pediatric Vaccines in India

Figure 23: Schedule for Pediatric Vaccines in Canada

Figure 24: Unmet Needs and Opportunities in Routine Pediatric Vaccines

Figure 25: Overview of the Development Pipeline in Routine Pediatric Vaccines, by Developer Location

Figure 26: Competitive Assessment of the Recently Approved and Late-Stage Pipeline Agents Expected to Launch During the Forecast Period

Figure 27: Analysis of the Company Portfolio Gap in Pediatric Vaccines During the Forecast Period

Figure 28: Global (9MM) Sales Forecast by Country for Pediatric Combination Vaccines in 2018 and 2028

Figure 29: Sales Forecast by Pediatric Combination Vaccine Type in the US in 2018 and 2028

Figure 30: Sales Forecast by Pediatric Combination Vaccine Type in the 5EU in 2018 and 2028

Figure 31: Sales Forecast by Pediatric Combination Vaccine Type in the Japan in 2018 and 2028

Figure 32: Sales Forecast by Pediatric Combination Vaccine Type in India in 2018 and 2028

Figure 33: Sales Forecast by Pediatric Combination Vaccine Type in Canada in 2018 and 2028

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports